Claims for Patent: 8,101,623

Summary for Patent: 8,101,623

Title:	Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor
Abstract:	The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I), methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
Inventor(s):	Richard William Arthur Luke, Zbigniew Stanley Matusiak
Assignee:	AstraZeneca AB
Application Number:	US12/249,477
Patent Claims:	1. The compound (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide: or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising the compound according to claim 1, or a pharmaceutically-acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier. 3. A method of treating breast cancer in a mammal comprising administering an effective amount the compound of claim 1, or a pharmaceutically acceptable salt thereof, to the mammal. 4. The compound (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo-[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide. 5. A pharmaceutical composition comprising the compound according to claim 4 together with a pharmaceutically acceptable diluent or carrier. 6. A method of treating breast cancer in a mammal comprising administering an effective amount of the compound of claim 4 to the mammal. 7. A process for the preparation of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, which comprises reaction of an acid of Formula (II) with (S)-3-amino-3-(4-chlorophenyl)propan-1-ol: wherein P1 represents a suitable protecting group; and thereafter: (i) removing the protecting groups; and, if necessary (ii) forming a pharmaceutically acceptable salt thereof. 8. The process as claimed in claim 7, wherein P1 represents a tert-butoxycarbonyl protecting group. 9. A process for the preparation of the compound claimed in claim 1, or a pharmaceutically acceptable salt thereof, which process comprises the reaction of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)piperidine-4-carboxamide with a bicyclic heterocycle of Formula (V): wherein L1 represents a suitable leaving group; and thereafter if necessary, forming a pharmaceutically acceptable salt thereof. 10. The process as claimed in claim 9, wherein L1 is chlorine.